← brief for 2026-11-12 · Slowing decline
SGLT2 inhibitors as foundational cardiorenal therapy: trial heterogeneity, evidence gaps, and practical sequencing in heart failure and chronic kidney disease
Key takeaways
This review explains how SGLT2 drugs help both the heart and kidneys. It notes that different trials had different patient groups. It discusses how to use these drugs in practice, but reports no new trial results.
Who did this work
Fayez Salahedin Alkhateeb (University of Jordan)
Source
Article · OpenAlex, CKD works · 2026-11-11
https://doi.org/10.1186/s43162-026-00761-5